Zindoxifene Explained

Zindoxifene (INN; former developmental code names D-16726, NSC-341952) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development in the 1980s and early 1990s for the treatment of breast cancer but was not marketed.^[1] It showed estrogenic-like activity in preclinical studies and failed to demonstrate effectiveness as a treatment for breast cancer in clinical trials.^{[2] [3]} Zindoxifene was the lead compound of the distinct 2-phenylindole class of SERMs,^{[4] [5]} and the marketed SERM bazedoxifene was derived from the major active metabolite of zindoxifene, D-15414. Zindoxifene was first described in 1984.

External links

• Zindoxifene - AdisInsight

Notes and References

1. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 1300–.
2. Book: Maximov PY, McDaniel RE, Jordan VC . The Legacy of Tamoxifen . Tamoxifen: Pioneering Medicine in Breast Cancer . https://books.google.com/books?id=p-W5BAAAQBAJ&pg=PA170. 23 July 2013. Springer Science & Business Media. 978-3-0348-0664-0. 170–.
3. Book: McDaniel R, Maximov PY, Jordan VC . The Legacy of Tamoxifen . Litwack G . Hormones and Breast Cancer. https://books.google.com/books?id=vBvzF6HQ4-QC&pg=PA32. 25 June 2013. Elsevier. 978-0-12-416676-9. 32–.
4. Book: Oettel M, Schillinger E . Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. 6 December 2012. Springer Science & Business Media. 978-3-642-58616-3. 68–69.
5. Book: Maggi A, Paoletti R . The Pharmacological Modulations of Estrogen Receptor Activity . International position paper on women's health and menopause : a comprehensive approach. 2002. https://books.google.com/books?id=NCzYsz6Uv0IC&pg=PA111. DIANE Publishing. 978-1-4289-0521-4. 111–.